Trial will be conducted by Angel Pharma and will study 12-week dosing of soquelitinib in patients with moderate-to-severe atopic dermatitisSOUTH...
The Award Highlights the Promise of Exclusively Targeting Peripheral Opioid Receptors to Treat Chronic Pain Without the Risk of Addiction...
MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX)...
Partnerships with Malawi, Hungary, and other new partners will rapidly expand BaseData, the largest biological protein database designed specifically for...
SUNNYVALE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a global leader in cellular and cell-derived therapeutics for the...
MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX)...
ProtoBind-Diff generates drug-like molecules for specific protein targets using only their amino acid sequences—no 3D structures required.The model performs competitively...
Strategic collaboration expands HealthLynked's focus on interoperability and digital transformation in hospital systems and EMRsNAPLES, Fla., June 25, 2025 (GLOBE...
PORTLAND, Maine, June 25, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company...
WESTON, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company...
CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the...
Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in...
- End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer’s Disease Scheduled - - Applications for IND and Breakthrough Status Filed...
Flipping the script on the traditional dispensary format, the new bodega-style shopping experience offers customers the freedom to browse and...
Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane,...
Phase 1/2a clinical trial currently supported by a $3.0 million grant from the U.S. Department of Defense Trial will enroll...
AGOURA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a clinical-stage...
PITTSBURGH, June 25, 2025 (GLOBE NEWSWIRE) -- MetasTx, LLC, a biotechnology company focused on preventing the metastasis of solid tumor...
Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In...
- The Joint to Deploy Capital and Enhance Profitability Profile by Reducing Regional Developer Count - - Largest Franchisee Signs...